Oncology Biosimilars Market to Reach US$ 12 Billion by 2032, Blood Cancer to Remain Primary Treatment Category: Fact.MR
Blood Cancer Segment Will Expand The Fastest, Expanding At A 10% CAGR During The Projected Period.
“Oncology clinical research has gained traction in recent years, and this trend has resulted in the discovery of various unique medications. Medical experts have paid close attention to leukemia research in particular. Given the aforementioned considerations, the worldwide oncology biosimilars market will gain traction in coming years,” says a Fact.MR Analyst.
Fact.MR – A Market Research and Competitive Intelligence Provider: The global oncology biosimilars market is expected to surge nearly 3x across the 2022-2032 forecast period, reaching US$ 12 Billion. As of 2022, the market is expected to garner a valuation of US$ 4.2 Billion. Advancements in cancer research to develop breakthrough therapeutics and diagnostics is expected to impel market growth in the future.
From 2015 to 2021, sales of oncology biosimilar drugs flourished at a CAGR of 9%, closing at a value of US$ 4 Billion. The increased incidences of cancer, such as lung cancer and breast cancer, a susceptible ageing population, and an increase in research and development efforts done by numerous pharmaceutical firms have all led to the expansion of the oncology biosimilars market.
Additionally, increased patient awareness, advancements in therapeutic approaches, and the high cost of biologics medications are all factors influencing the demand for oncology biosimilars. Conversely, product recalls, allied with restrictive regulations, are factors inhibiting the growth of this sector. Because of the increasing frequency of cancer and the increase in the number of FDA-approved medications, North America has seen a good expansion in the oncology biosimilars market throughout the anticipated period.
For more insights into the Market, Get A Sample of this Report!
Key Takeaways from the Market Study
- Demand for oncology biosimilars is expected to grow at an 11% CAGR between 2022 and 2032.
- By 2032, the oncology biosimilars market in the United States will reach US$ 5.6 Billion by 2020.
- China is expected to register a 7.7% CAGR with regard to the Oncology Biosimilars industry
- Japan is expected to document a CAGR worth 7.5% in the Oncology Biosimilars market
- The neutropenia segment is expected to grow at a rapid 7% CAGR over the assessment period.
The worldwide market for oncology biosimilars is a highly consolidated market. The top five market participants jointly account for more than 70% of the market share. To expand their market footprints, these companies rely heavily on active collaborations to boost their product distribution networks.
- In 2018, Biocon, for example, established an exclusive global agreement with Sandoz on next-generation biosimilars. Similarly, Dr. Reddy's cooperated with TR Pharm in 2016 to offer three biosimilars in Turkey. Pfizer, Inc., Celltrion, Inc., Sandoz International GmBH, STADA Arzneimittel AG, and Apotex, Inc. are some of the other significant industry participants in the global oncology biosimilars market.
- Atos has announced recently in April 2022 that it intends to forge a 5-year contractual agreement to deliver managed services for digital operations, applications and cybersecurity for Independent Health (IH). Atos’ operational solutions will leverage infrastructure and digital platforms to optimize operating costs and generate efficiencies across the business landscape.
For Comprehensive Insights Ask An Analyst Here https://www.factmr.com/connectus/sample?flag=AE&rep_id=4800 Key Segments Covered in the Oncology Biosimilars Industry Report
- Oncology Biosimilars by Drug
- Monoclonal Antibody
- Hematopoietic Agents
- Oncology Biosimilars by Disease Indication
- Breast Cancer
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Blood Cancer
- Myeloid Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin Lymphoma
- Oncology Biosimilars by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Oncology Biosimilars by Region
- North America
- Asia Pacific
- Rest of the World
Get Customization on this Report for Specific Research Solutions https://www.factmr.com/connectus/sample?flag=RC&rep_id=4800 Fact.MR’s Domain Knowledge in Healthcare
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
Check out more studies related to Healthcare Industry, conducted by Fact.MR:
Aesthetic Medicine Market - Aesthetic Medicine Market Analysis by Procedure Type (Invasive Procedures, Non-Invasive Procedures), by Region - Global Forecast 2022-2032
Regulatory Affairs Outsourcing Market - Regulatory Affairs Outsourcing Market by Services (Regulatory Consulting Outsourcing, Legal Representation Outsourcing), by Category (Drugs, Biologics), by Indication (Oncology, Neurology, Radiology), by Stage, by Company Size, by End Use & Regional Forecast 2022-2032
mHealth Apps Market - mHealth Apps Market Analysis by Product Type (Medical Apps [Women’s Health Apps, Personal, Health Record Apps, Medication Management Apps, Diagnostic Apps], Fitness Apps [Diet & Nutrition, Exercise & Fitness, Lifestyle & Stress]), by Region - Global Forecast 2022-2032
Biotechnology & Pharmaceutical Services Outsourcing Market - Biotechnology & Pharmaceutical Services Outsourcing Market Analysis by Service (Product Testing & Validation, Training & Education, Product Design & Development, Product Maintenance, Regulatory Affairs, Consulting), by End Use & Region - Global Forecast 2022-2032
Electronic Health Records Market - Electronic Health Records Market Analysis by Product (Client-server-based HER, Web-based HER), by Type (Acute, Ambulatory, Post-acute Electronic Health Records), by Business Model, by End Use, by Region - Global Forecast 2022-2032
Home Infusion Therapy Market - Home Infusion Therapy Market Analysis By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needless Connectors), By Application (Anti-infective, Endocrinology, Hydration Therapy, Chemotherapy, Parenteral Nutrition), By Region - Global Insights 2022 to 2032
Skincare Devices Market - Skincare Devices Market Analysis by Product (Diagnostic Devices [Dermatoscopes, Microscopes, Biopsy Devices], Treatment Devices [Light Therapy Devices, Electrosurgical Equipment, Liposuction Devices, Cryotherapy Devices]), by Application, by End Use & Regional Forecast 2022-2032
Clear Aligners Market - Clear Aligners Market Analysis by Age Outlook (Adults, Teens), by End-use Outlook (Hospitals, Standalone Practices, Group Practices), by Region - Global Forecast 2022-2032
Dental Laboratories Market - Dental Laboratories Market Analysis By Type (Restorative, Orthodontic, Endodontic, Oral care, Implant), By Application (Dental Radiology Equipment, Dental Lasers, Systems & Parts), By Region - Global Insights 2022-2032
Biomarkers Market - Biomarkers Market Analysis by Disease Type (Cardiovascular Diseases, Cancer, Neurological Diseases, Immunological Diseases), by Type (Safety, Efficacy, Validation Biomarkers), by Application & by Region - Global Forecast 2022-2032
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.